nifedipine has been researched along with Parkinson Disease, Secondary in 4 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| " A similar dose-response relationship was determined for nifedipine, an L-type calcium channel antagonist." | 1.31 | Pharmacological involvement of the calcium channel blocker flunarizine in dopamine transmission at the striatum. ( Armando, I; Belforte, JE; Buño, W; Magariños-Azcone, C; Pazo, JH, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaur, U | 1 |
| Das, P | 1 |
| Gambhir, IS | 1 |
| Chakrabarti, SS | 1 |
| Haghdoost-Yazdi, H | 1 |
| Hosseini, SS | 1 |
| Faraji, A | 1 |
| Nahid, D | 1 |
| Jahanihashemi, H | 1 |
| Belforte, JE | 1 |
| Magariños-Azcone, C | 1 |
| Armando, I | 1 |
| Buño, W | 1 |
| Pazo, JH | 1 |
| Fernandez Pardal, M | 1 |
| Fernandez Pardal, J | 1 |
| Micheli, F | 1 |
4 other studies available for nifedipine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
L-type calcium channel blockers and a symptom complex mimicking de Melo-Souza's syndrome.
Topics: Aged; Amlodipine; Calcium Channel Blockers; Calcium Channels, L-Type; Diagnosis, Differential; Femal | 2019 |
Long term exposure to norharman exacerbates 6-hydroxydopamine-induced parkinsonism: possible involvement of L-type Ca2+ channels.
Topics: Analysis of Variance; Animals; Behavior, Animal; Brain; Calcium Channel Blockers; Calcium Channels, | 2010 |
Pharmacological involvement of the calcium channel blocker flunarizine in dopamine transmission at the striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Calcium Channel Blockers; Calcium Channels, L- | 2001 |
Aggravation of Parkinson's disease by cinnarizine.
Topics: Animals; Caudate Nucleus; Cinnarizine; Dopamine; Flunarizine; Male; Nifedipine; Parkinson Disease, S | 1988 |